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Abstract: Doping with anabolic agents is a topic in sports where strength is crucial, e.g. sprinting, weight lifting and many 
more. Testosterone and its functional analogs are the drugs of choice taken as pills, creams, tape or injections to increase 
muscle mass and body performance, and to reduce body fat. Stanozolol (17β-hydroxy-17α-methyl-5α-androst-
2-eno[3,2c]pyrazol) is a testosterone analogue with the same anabolic effect like testosterone but its ring structure makes it 
possible to take it orally. Therefore, stanozolol is one of the most frequently used anabolic steroids.
Common veriﬁ  cation methods for anabolic drugs exist, identifying the chemicals in tissues, like hair or blood samples. The 
idea of this feasibility study was to search for speciﬁ  c gene expression regulations induced by stanozolol to identify the 
possible inﬂ  uence of the synthetically hormone on different metabolic pathways. Finding biomarkers for anabolic drugs 
could be supportive of the existing methods and an additional proof for illegal drug abuse.
In two separate cell cultures, human HFDPC (hair follicle dermal papilla cells) from a female and a male donor were treated 
with stanozolol. In the female cell culture treatment concentrations of 0 nM (control), 1 nM, 10 nM and 100 nM were cho-
sen. Cells were taken 0 h, 6 h, 24 h and 48 h after stimulation and totalRNA was extracted. Learning from the results of the 
pilot experiment, the male cell culture was treated in 10 nM and 100 nM concentrations and taken after 0 h, 6 h, 24 h and 
72 h. Using quantitative real-time RT-PCR expression of characteristics of different target genes were analysed.
Totally 13 genes were selected according to their functionality by screening the actual literature and composed to functional 
groups: factors of apoptosis regulation were Fas Ligand (FasL), its receptor (FasR), Caspase 8 and Bcl-2. Androgen receptor 
(AR) and both estrogen receptors (ERα, ERβ) were summarized in the steroid receptor group. The growth factor group 
included the insulin like growth factor receptor (IGF1R) and growth hormone receptor (GHR). Fibroblast growth factor 2 
(FGF2) and keratinocyte growth factor (FGF7) were summarized in the hair cycle factor group. 5α-Steroidreductases 
(SRD5A1, SRD5A2) represented the enzyme group. Three reference genes were taken for relative quantiﬁ  cation: ubiquitin 
(UBQ), glycerinaldehyde-3-phsophate-dehydrogenase (GAPDH), and β-actin (ACTB).
In cell culture 1 AR, FasR, FGF2 showed signiﬁ  cant regulations within one treatment time, signiﬁ  cant gene expressions 
over time were analysed for Caspase 8. In cell culture 2 AR, FasR and SRD5A2 were signiﬁ  cantly regulated within one 
treatment time.
In this feasibility study ﬁ  rst biomarker for a screening pattern of anabolic agents could be identiﬁ  ed providing the rationality 
to investigate modiﬁ  ed, metabolic pathways in the whole hair follicle.
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Introduction
Anabolic androgenic steroids (AAS) are misused by athletes because of their anabolic properties. Main 
functions of AAS are stimulation of protein synthesis and an antiglucorticoid effect which increases 
muscle mass and strength. They inﬂ  uence the central nervous system and increase motivation and 
performance (Duntas et al. 2003; Hartgens et al. 2004; Hickson et al. 1990; Griggs et al. 1989; Kuhn, 
2002). The International Olympic Committee banned the use of synthetic AAS in 1974 by athletes but 
today doping is still a big topic in almost all kinds of sport. The world anti doping agency (WADA) 
encourages drug testing laboratories to develop methods to detect AAS like testosterone, 
17β-nortestosterone and stanozolol that are the most frequently found steroids in doping samples (Kuhn, 
2002; Clasing and Mueller, 2006; Schänzer, 1996). Common used methods in doping analysis are mass 
spectrometry (MS) based techniques, that directly detect the AAS or their metabolites in different tissues 
like urine, blood or hair samples. Especially the hair is a very interesting tissue for drug residue analysis 
because hormones are detectable over a long time and the samples are easily to collect by a non invasive 2
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manner (Gleixner et al. 1996; Catlin et al. 1997; 
Thieme et al. 2000; Ayotte, 2006; Anielskie et al. 
2005; Gambelunghe et al. 2007). The intake of 
AAS inﬂ  uences the organism in many different 
ways. It can be supposed that these hormonally 
provoked changes in the metabolism can be seen 
on the level of mRNA gene expression (Reiter et al. 
2007). Taking the hair root to analyse these expres-
sions it is known that androgens act via the dermal 
papilla cells and inﬂ  uence different kind of growth 
factors and enzymes (Stenn and Paus, 2001).
The aim of this feasibility study was to inves-
tigate regulated target genes in hair follicle cells 
to identify possible mRNA gene expression regu-
lations aroused by stanozolol. Target genes were 
selected in functional groups to facilitate the iden-
tiﬁ  cation of possible biomarker for the different 
hormones.
Materials and Methods
Reagent
The anabolic steroid stanozolol (S, 17β-Hydroxy-
17α-methyl-androstano[3,2-c]pyrazole), was 
received from Sigma-Aldrich (Taufkirchen, 
Germany) with cell culture grade purity. For treat-
ment the reagents was dissolved in 100% ethanol 
to a concentration 1mg/ml and diluted with cell 
culture medium to 1 nM, 10 nM and 100 nM.
Experiment
Two HFDPC (hair follicle dermal papilla cell) 
cultures, one from a female (cell culture 1) and one 
from a male (cell culture 2) donor were treated in 
different concentrations with the anabolic steroid 
stanozolol and taken at different treatment time 
points.
Cell culture 1
Human HFDPC were ordered from Cell Applica-
tions (San Diego, U.S.A). Cells had been cultivated 
from skin samples of the temple taken during 
plastic surgery at a 49 year-old, female patient. 
After establishing a primary cell culture the cells 
were frozen in serum-free freezing medium and 
sent cryopreserved (500,000 cells in 1ml). A ready-
to-use HFDPC Medium and Supplement Kit (Cell 
Applications, San Diego, U.S.A) was taken to 
cultivate the cells, containing Basal Medium, FCS 
(fetal calf serum), growth factors and antibiotics. 
For sub cultivation served a kit containing HBSS 
(HEPES buffered saline solution), trypsin/EDTA 
solution and neutralizing solution (Cell Applica-
tions, San Diego, U.S.A).
The thawed cells were cultivated in collagen 
coated T-75 ﬂ  asks (Cell Applications, San Diego, 
U.S.A) containing 15 ml HFDPC medium at 37 °C 
in a humidiﬁ  ed atmosphere of 5% CO2 and sub-
cultivated at 85% conﬂ  uence. Cells were frozen 
and stored at −80 °C after each splitting that was 
up to the sixth passage. For the experiment cells 
from third passage were thawed, given into 12-well 
plates (ca. 3.4 × 10
4/well) and cultivated till 85% 
conﬂ  uence. Cells were cultured in triplicates with 
0 nM (control-treatment), 1 nM, 10 nM and 100 nM 
stanozolol groups on each plate, sampling took 
place at 0 h (control-time), 6 h, 24 h and 48 h.
To remove natural containing steroids for all 
experiments the FCS was stripped by using char-
coal, as described by Darbre et al. (1983).
Cell culture 2
Human HFDPC cells were ordered from Promo 
Cell (Heidelberg, Germany). Cells had been culti-
vated from skin samples of the temple taken during 
plastic surgery at a 40 year-old, male patient. After 
establishing a primary cell culture the cells were 
frozen in serum-free freezing medium and sent 
cryopreserved (500,000 cells in 1ml). A ready-
to-use HFDPC Medium and Supplement Kit 
(Promo Cell, Heidelberg, Germany), containing 
Basal Medium, FCS (fetal calf serum), basic FGF 
and Insulin was additionally ordered to cultivate 
the cells. For sub cultivation served a kit contain-
ing HBSS (HEPES buffered saline solution), 
trypsin/EDTA solution and neutralizing solution 
(Promo Cell, Heidelberg, Germany).
Cells were cultivated in T-75 ﬂ  ask with 15 ml 
Medium at 37 °C in a humidiﬁ  ed atmosphere of 
5% CO2 and sub-cultivated at 85% conﬂ  uence. 
Collagen coating was not executed because it was 
not recommended by the supplier. Cells were 
frozen and stored at −80 °C after each splitting that 
was up to the sixth passage. For the experiment the 
cells from third passage were given into 12-well 
plates (ca. 3.4 × 10
4/well) and cultivated till 
85% conﬂ  uence. Cells were cultured in triplicates 
with 0 h (control-treatment), 10 nM and 100 nM 
stanozolol groups on each plate, sampling took 
place 0h (control-time), 6 h, 24 h and 72 h.3
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For treatment, steroids were removed from FCS, 
as described by Darbre et al. (1983).
RNA extraction and RNA quality
Total RNA was isolated from HFDPC cells using 
TriFast (peqLab Biotechnologie GmbH, Erlangen, 
Germany). The standardized protocol from the 
supplier was used for the extraction. The principal 
of this protocol was phenol/chloroform extraction 
for total RNA. Extracted RNA was dissolved in 
10 μl RNAse free water. To quantify the amount 
of total RNA extracted, optical density (OD) 
was measured with the photometer (Eppendorf 
Biophotometer, Hamburg, Germany) for each 
sample.
RNA integrity and quality control was performed 
with the Bioanalyzer 2100 (Agilent Technology, 
Palo Alto, U.S.A). For sample analysis eukaryotic 
total RNA Nano Assay (Agilent Technology) was 
taken and the RNA Integrity Number (RIN) served 
as RNA quality parameter (Fleige et al. 2006, 
Schroeder et al. 2006). In order to the expected 
high quality of the total RNA from cell cultures, a 
set of selected samples from the 6 h treatment were 
measured as quality references.
Selection of target genes
Target genes (TG) were selected according to their 
possible role in the anabolic pathways in the hair 
follicle. Following TG were chosen as markers by 
screening the respective literature. Because of the 
limited total RNA amount, TG were taken for 
analysis that seemed to be highly inﬂ  uenced by 
steroids and could show possible gene expression 
regulations.
Factors of apoptosis regulation were Fas 
receptor ligand (FasL), Fas receptor (FasR), 
Caspase 8 and the anti-apototic factor Bcl-2. 
Androgen receptor (AR) and the estrogen receptors 
(ERα, ERβ) were summarized in the steroid 
receptor group. The growth factor group included 
the insulin like growth factor receptor (IGF1R) and 
growth hormone receptor (GHR). Fibroblast 
growth factor 2 (FGF2) and keratinocyte growth 
factor (FGF7) were summarized in the hair cycle 
factor group. 5α-Steroidreductases (SRD5A1, 
SRD5A2) represented the enzyme group.
Ubiquitin (UBQ), glycerinaldehyde-3-phsophate-
dehydrogenase (GAPDH) and β-actin (ACTB) were 
taken as reference genes for relative quantiﬁ  cation 
method.
Primer design and testing
All primers were designed using published nucleic 
acid sequences of “Ensembl Genom Browser” (http://
www.ensembl.org) and NCBI (www.ncbi.nlm.nih.
gov). Primer design and optimization was done with 
primer design program primer 3 (http://frodo.wi.mit.
edu/) with regard to primer dimer formation, self-
priming formation and primer annealing temperature 
at 60 °C. Designed primers were ordered, synthesized 
and shipped by MWG Biotech (Ebersberg, Germany). 
Primer testing was performed with a pooled RNA 
sample of several hair samples, as positive control 
and RNAse free water as negative control (Qiagen, 
Hilden, Germany) for each primer set. Generated 
PCR products were checked for length and primer 
dimer formation by an agarose gel electrophoresis. 
All primer sequences, their amplicon size and anneal-
ing temperatures are illustrated in Table 1.
Real-time qRT-PCR
Quantitative real-time RT-PCR was performed at 
the Rotor Gene 6000 (Corbett Life Science, Sydney, 
Australia) using SuperScript III Platinum SYBR 
Green One-Step qPCR Kit (Invitrogen, Carlsbad, 
U.S.A) by using standard protocol of the supplier. 
Samples were diluted to 10 ng/μl. For mRNA pro-
tection, additionally 50 ng tRNA in 5 μl (Invitrogen, 
Carlsbad, U.S.A) were added to each sample. 3.8 μl 
of total RNA solution were taken for one PCR 
reaction in a total volume of 10 μl. Threshold cycle 
(Ct) and melting curves were acquired by using the 
“quantitation” and “melting curve” program of 
the Rotor-Gene 6000 analysis software.
Only genes with clear and single melting peaks 
were taken for further data analysis. Samples with 
irregular melting peaks were excluded from the 
calculation. All samples were baseline corrected and 
threshold was set manually, using identical thresh-
old levels for one gene in all analyzed samples.
Data Analysis and Statistics
Data were processed applying relative quantiﬁ  ca-
tion method comparable to the ΔΔCt-method 
(2
−ΔΔCt) (Livak et al. 2001). Expression changes 
are shown as relative up- or down-regulation nor-
malized by three internal reference genes. For 
normalization of target gene expression the arith-
metic mean (AM) of the following reference 
genes (RG) were taken: (RG1) GAPDH, (RG2) 
ACTB and (RG3) UBQ. The mean values served 4
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Table 1. List of used primer pairs, showing the length of the amplicon (nt), the melt temperature (Tm in °C) and 
the accession number of the sequence.
Group Identity Sequence 5’-3’ Amplicon (nt) Tm (°C) Acces. Nr.
Enzymes SRD5A1 FOR CTT GAG CCA TTG 
TGC AGT GT
166 58 ENST00000233239
REV GCC TCC CCT TGG TAT 
TTT GT
SRD5A2 FOR TGA ATA CCC TGA TGG 
GTG GT
181 60 ENST00000233139
REV GGA AAT TGG CTC 
CAG AAA CAT A
Growth 
factors
GHR FOR ATC CAC CCA TTG 
CCC TCA AC
246 60 NM00163
REV ATC TCA CAC GCA CTT 
CAT ATT CC
IGF1R FOR CAT TTC ACC TCC ACC 
ACC AC
151 60 NM000875
REV AGG CAT CCT GCC 
CAT CAT AC
Hair cycle FGF2 FOR AGA AGA GCG ACC 
CTC ACA TC
237 60 M27968
REV ACT GCC CAG TTC 
GTT TCA GT
KGF/FGF7 FOR CCT GAG CGA CAC 
ACA AGA AG
167 60 M60828
REV GCC ACT GTC GCT 
TCC TTA TT
Apoptosis 
factors
FasR FOR TTC TGC CAT AAG CCC 
TGT CC
174 60 NM000043
REV CCA CTT CTA AGC CAT 
GTC CTT C
bcl2 FOR GAG GAT TGT GGC 
CTT CTT TGA G
170 60 NM000633
REV ACA GTT CCA CAA 
AGG CAT CCC
Caspase 8 FOR TGG CAC TGA TGG 
ACA GGA G
230 60 NM001228
REV GCA GAA AGT CAG 
CCT CAT CC
Steroid 
receptors
AR FOR TTG TCC ATC TTG TCG 
TCT TCG G
237 60 L29496
REV TGT CCA GCA CAC 
ACT ACA CC
Reference 
genes
UBQ FOR TGA AGA CTC TGA CTG 
GTA AGA CC
128 60 NM021009
REV CAT CCA GCA AAG ATC 
AGC CTC
GAPDH FOR GAA GGT GAA GGT 
CGG AGT CAA
233 60 NM002046
(Continued)5
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as reference gene index (RGI). RG were excluded 
when showing signiﬁ  cant regulation by treatment 
or time. This was calculated using the t-test algo-
rithm in Excel (Microsoft, U.S.A). This value was 
then taken to do normalization and calculate the 
ΔCt by subtracting the Ct of the RG-Index (RGI) 
from the Ct of the target gene (TG).
RGI (cell culture 1) = AM (CtACTB; CtGAPDH; CtUBQ)
RGI (cell culture 2) = AM (CtGAPDH; CtUBQ)
ΔCt = Ct (RGI) – Ct (TG)
In a second step the normalized gene expression 
values were set in relation to the control group 
(ΔΔCt).
ΔCt  (control/treatment) = mean ΔCt value of control treatment
ΔΔCt = ΔCt (treatment) – ΔCt (control/treatment)
To show up- and down-regulations of the TG 
the ratio was calculated provided that DNA was 
doubled per cycle (2
ΔΔCt).
Ratio = 2
ΔΔCt
Regulations over treatment time were calculated 
using a 2-Way-Anova with SigmaStat Software. 
In Excel (Microsoft, U.S.A) ΔΔCt was calculated 
and statistical analyses were done by using the 
t-test. All data are illustrated by means ± standard 
deviation (SD).
Results
RNA concentration and RNA integrity
Samples of the cell culture 2 showed a slightly 
higher mean RNA yield (144.78 ng/μl) compared 
to the samples of the cell culture 1 (76.9 ng/μl). 
For the 6 h treatment samples average RIN values 
were quite similar in cell culture 1 (8.8 ± 0.5) and 
in cell culture 2 (8.6 ± 2.9).
Primer testing and PCR
From 19 designed and tested primer pairs three 
genes did not showed satisfactory PCR results, 
concerning veriﬁ  ability, melting curve analysis and 
in agarose gel electrophoresis. Therefore, FasL, ERα 
and ERβ were excluded from analysis. All other 
genes were accepted for further analysis.
Gene regulation under Stanozolol 
treatment
Because the reference gene ACTB showed a 
signiﬁ  cant regulation under stanozolol treatment 
in cell culture 2, only GAPDH and UBQ were taken 
for RGI calculation.
Gen expression analysis within one 
treatment time point (ΔΔCt)
In both cell cultures AR showed a signiﬁ  cant down 
regulation after 24 h and FasR an up- regulation 
after 6 h of stanozolol treatment. In cell culture 1 
the regulation of AR was seen in the 1nM concen-
tration (p = 0.047), in cell culture 2 in the 100 nM 
concentration (p = 0.014). FasR was up-regulated 
at 6 h for 10 nM concentration in cell culture 1 
(p = 0.023) and cell culture 2 (p = 0.049). Addition-
ally FGF7 was down-regulated at 0 h (100 n M, 
p = 0.009, 10 nM, p = 0.0d46) and at 6 h (100 nM, 
p = 0.03) in cell culture 1, in cell culture 2 SRD5A2 
(6 h, 100 nM, p = 0.028) and FGF2 (0 h, 100 nM, 
p = 0.010) showed a signiﬁ  cant down-regulation 
(Figs. 1, 2).
Gen expression over treatment time 
(2-Way-Anova)
In the 2-Way-Anova one signiﬁ  cant combination of 
Caspase 8 to treatment concentration (p-value = 0.010) 
and treatment time (p-value = 0.028) could be 
calculated in cell culture 1. Caspase 8 in the 1nM 
concentration was signiﬁ  cantly different from all 
other concentrations and signiﬁ  cant differences 
between 0 h to 6 h (p-value = 0.035) and 0h to 48 h 
(p-value = 0.029) could be measured for this gene.
Table 1. (Continued)
Group Identity Sequence 5’-3’ Amplicon (nt) Tm (°C) Acces. Nr.
REV GCT CCT GGA AGA 
TGG TGA TG
ACTB FOR AGTCCTGTGGCATCC
ACGAAAC
78 60 NM01101
REV GCAGTGATCTCCTTCT
GCATCC6
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Gene expression regulations in cell cultrue 2
treatment groups
Control 100 nM 10 nM
2
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C
t
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AR-24 h
FGF2- 0 h
SRD5A2-6 h
FasR-6 h
Plot 1 Upper control line
*
** *
Figure 2. Signiﬁ  cant gene expression regulations in cell culture 2. The ratio was calculated by 2
ΔΔCt whereby the control was set 1 (upper 
control line). Data are depicted in bars + standard deviation. Red crosses (*) mark the signiﬁ  cantly regulated target genes.
Gene expression regulations in cell culture 1
treatment groups
Control 100 nM 10 nM 1 nM
2
Δ
Δ
C
t
0
2
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6
8
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16
AR-24-h
FasR-6 h
FGF7-0 h
FGF7-6 h 
Plot 1 Upper control line
*
*
*
*
*
Figure 1. Signiﬁ  cant gene expression regulations in cell culture 1. The ratio was calculated by 2
ΔΔCt whereby the control was set 1 (upper 
control line). Data are depicted in bars + standard deviations. Red crosses (*) mark the signiﬁ  cantly regulated target genes.7
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Discussion
In the present study it was tested weather the AAS 
stanozolol induces speciﬁ  c gene expression regu-
lations in HFDPC. Taking the indicated target 
genes, ﬁ  rst potential genes for an expression pat-
tern could be identiﬁ  ed. As feasibility study the 
experiments were done in cell culture to identify 
a set of target genes possibly interesting for further 
analysis in human hair follicle samples.
As expected, all cell culture samples showed a 
very high RNA quality, a precondition for good 
qRT-PCR results.
Signiﬁ  cant regulations over the time period of 
treatment were supposed to show trends in gene 
regulations. The separation in different functional 
groups could help to identify gene dependent 
pathways in the hair papilla. Signiﬁ  cant inﬂ  uences 
of stanozolol on gene expression could be shown 
up to an incubation time of 24 h. After this time 
the xenobiotic steroid seems to have less inﬂ  uence 
on gene expressions. This kind of time dependent 
gene expression regulations were also shown in 
other studies (Black et al. 1992; Schönfelder and 
Einspanier, 2003). Most regulations could be seen 
at 10 nM and 100 nM treatment levels. In both 
cell cultures AR and FasR showed the same gene 
expression characteristics under stanozolol treat-
ment at the same time point of treatment. FasR 
additionally showed comparable regulations at 
the same hormone concentration. This makes AR 
and FasR to the ﬁ  rst interesting candidate genes 
for a gene expression pattern of stanozolol. Also 
a possilbet gender speciﬁ  c difference could be 
seen because in the male cells the effects of the 
treatment seemed to induce regulations earlier 
(6 h) than in the female samples (24 h) (Melchert 
et al. 1992).
Next to the gender speciﬁ  c effects on gene 
regulation also the growth phase of the hair follicle 
could inﬂ  uence the results. A ﬁ  rst hind for this 
assumption could be the different regulations of 
FGF2 and FGF7 in the untreated samples in both 
cultures. FGF7 is known to induce the growth 
phase (anagen phase) in the hair follicle, whereas 
FGF2 could be taken as its antagonist by inhibiting 
the morphogenesis (Stenn and Paul, 2001). In cell 
culture 1 FGF7 was signiﬁ  cantly down-regulated 
what would show that these cells were taken from 
a hair follicle in the catagen phase. In cell culture 
2 FGF2 was signiﬁ  cantly down-regulated, indicat-
ing the anagen phase. Anyhow the signiﬁ  cant 
regulation of FGF2 was a surprise because several 
studies identiﬁ  ed this factor in the hair follicle but 
not in the hair papilla (Mitusi et al. 1997; Ota et al. 
2002; Schlake et al. 2005).
The signiﬁ  cant regulation of FasR and Caspase 
8 in cell culture 1 showed ﬁ  rst inﬂ  uences on meta-
bolic pathways. The regulation of both factors could 
indicate a possible inﬂ  uence of stanozolol on the 
extrinsic way of apoptosis (Reiter et al. 2006).
The signiﬁ  cant regulation of IGF1-R is sup-
posed to be an effect of the HFDPC medium 
because this was already analysed in different stud-
ies before (Philpott et al. 1994; Weger et al. 2005; 
Tang et al. 2003).
Conclusion
In this feasibility study ﬁ  rst steps toward a new 
screening method via gene expression analysis in 
hair follicle were explored. A set of 10 genes was 
tested in cell culture to identify possible candidate 
genes and physiological inﬂ  uences of stanozolol 
in the hair papilla. Factors like gender and growth 
phase of the hair follicle seem to inﬂ  uence gene 
expression patterns in the cells. Additionally FGF2 
known to be expressed in the hair follicle was 
identiﬁ  ed in the hair papilla. AR and FasR can be 
taken as ﬁ  rst candidate genes for a stanozolol 
treatment pattern because they showed same regu-
lations at the same time point in male and female 
cell cultures.
Further studies are needed to identify more can-
didate genes and exclude individual differences in 
gene expression. Anyhow, in the future the identiﬁ  ed 
substance speciﬁ  c candidate genes could be used 
for further analysis in hair follicle samples taken 
from athletes to identify possible treatment with 
anabolic agents. This could be supportive of the 
existing test methods in doping analysis and could 
be an additional proof for illegal drug abuse.
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